CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that its abstract was accepted for presentation at the ASCO 2022 Annual Meeting, taking place from June 3-7, 2022 in Chicago, IL. The poster titled 'Design and initiation of an adaptive, randomized, controlled study of berubicin for recurrent glioblastoma multiforme' will be presented by Dr. Sandra L. Silberman on June 5, 2022. Berubicin is noted as the first anthracycline able to cross the blood-brain barrier and aims to treat aggressive brain cancers. This represents a significant milestone in CNSP's development of innovative cancer therapies.
- Abstract accepted for ASCO 2022 Annual Meeting, enhancing visibility.
- Berubicin demonstrates promise against recurrent glioblastoma multiforme.
- Potential breakthrough in crossing the blood-brain barrier.
- None.
HOUSTON, May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting being held virtually and in Chicago, IL from June 3-7, 2022.
Details of the accepted abstract are as follows:
Abstract Title: | Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy |
Abstract Number: | TPS2083 |
Presenter: | Sandra L. Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals |
Session Type/Title: | Poster Session/Central Nervous System Tumors |
Session Date and Time: | Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT |
For more information about the ASCO 2022 Annual Meeting, please visit conferences.asco.org.
About Berubicin
Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company's cash runway to extend until Q1 2022 and the timing of patient dosing to commence. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-acceptance-of-abstract-for-poster-presentation-at-the-american-society-of-clinical-oncology-asco-2022-annual-meeting-301549620.html
SOURCE CNS Pharmaceuticals, Inc.
FAQ
What is CNS Pharmaceuticals' stock symbol?
When is the ASCO 2022 Annual Meeting?
What is the significance of berubicin in CNS Pharmaceuticals' research?
Who will present the abstract at the ASCO meeting?
What is the title of the abstract presented by CNS Pharmaceuticals?
